Filtered By:
Source: Value in Health
Drug: Coumadin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
MT45 Cost-Effectiveness Analysis of Left Atrial Appendage Closure (LAAC) Device Vesus Warfarin and New Oral Anticoagulants (NOACS) in Patients with Atrial Fibrillation (AF) - Large Brazilian Healthcare Payer Perspective
The objective of the study was to evaluate the cost-effectiveness of LAAC with WATCHMAN device in the perspective of a large Brazilian healthcare payer with more than 18 million patients.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: H. Tortele, S. Rodrigues, Cont ó M Source Type: research
CO4 Outcomes of Non –Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies
This study aimed to ident ify differences between original studies of NOACs vs warfarin to support interpretation of results across studies.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: R. Wang, H. Lien, A. Borrow, D. Fleishman Source Type: research
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country
This study assessed the cost-effectiveness of DOACs compared to warfarin with varying anticoagulation controls for stroke prevention in NVAF patients in real-world setting in Thailand.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M.S. Syeed, T. Nonthasawadsri, R.E. Nelson, N. Chaiyakunapruk, S. Nathisuwan Source Type: research
CO55 Efficacy and Safety of Direct Oral Anticoagulants (DOACS) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: A Systematic Review and Meta-Analysis
The purpose of this meta-analysis was to compare efficacy and safety of direct oral anticoagulants (DOACs) to warfarin for secondary stroke prevention among adult patients with atrial fibrillation and prior stroke.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: K Umashankar, M Mammi, E Badawoud, Y Tang, M Zhou, JC Borges, A Liew, M Migliore, RA Mekary Source Type: research
P73 Real-World Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Patients with Non-Valvular Atrial Fibrillation (NVAF): A Retrospective Cohort Study in Singapore
This study aims to compare the real-world effectiveness and safety between NOAC and warfarin in NVAF patients and assess the potential long-term impact on the healthcare system in Singapore.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: W. Foo, T. Hui, S.K.B. Ong, K.H. Ng Tags: Real-World Evidence for Comparative Effectiveness, Safety and Adherence Evaluations Source Type: research
EE411 Healthcare Costs of Direct Oral Anticoagulants Among Medicare Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
To evaluate cost differences between stroke/systemic embolism (S/SE) and major bleeding (MB) among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity prescribed direct oral anticoagulants (DOACs) or warfarin.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, R Thomas, G Leung, B Emir, H Yuce, M DiFusco Source Type: research
PCV57 Persistence to Warfarin Among Patients with Atrial Fibrillation and Comorbid Hypertension, Diabetes and Hyperlipidemia
The objective of this study was to examine the persistence to Warfarin and to evaluate the predictors associated with non-persistence to Warfarin among patients with comorbid AF, diabetes, hypertension, and hyperlipidemia.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: A. Mohan, Z. Majd, R. Paranjpe, A. Vadhariya, O. Serna, S.M. Abughosh Source Type: research
Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function.
Source: Value in Health - July 24, 2018 Category: International Medicine & Public Health Authors: Shoroq M. Altawalbeh, Osama Y. Alshogran, Kenneth J. Smith Source Type: research
Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstan
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: A Kostyuk, A Almadiyeva, T Nurgozhin Source Type: research
Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research
Health Care Cost In Patients Undergoing Electrical Cardioversion: An Analysis From The Edoxaban Versus Warfarin In Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Study
Electrical cardioversion (EC) restores and maintains sinus rhythm in atrial fibrillation (AF) patients. Edoxaban, a direct oral anticoagulant indicated for prevention of stroke or systemic embolic event (SEE) in patients with non-valvular atrial fibrillation (NVAF) was compared with enoxaparin –warfarin in patients undergoing EC in ENSURE-AF (NCT 02072434) study, a phase 3b open-label, multi-national open-label trial comparing edoxaban with enoxaparin/warfarin followed by warfarin alone in 2,199 NVAF patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: J Rodriguez Barrrios, A Goette, J Kwong, MD Ezekowitz, M Banach, SP Hjortsh øj, D Zamoryakhin, G Lip Source Type: research
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
Trends in the Utilization of Warfarin and Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
Warfarin has been used for more than 60 years to decrease the risk of stroke and death in patients with atrial fibrillation (AF). In recent years, the FDA has approved four non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in AF: dabigatran, rivaroxaban, apixaban, and edoxaban.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Alalwan, S Voils, A Hartzema Source Type: research
Patterns and Predictors of Discontinuation and Switch in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Recent clinical trials have established non-vitamin K antagonist oral anticoagulants (NOACs) as viable alternatives to warfarin in stroke prevention for atrial fibrillation. A major challenge in routine clinical practice is the high rate of medication discontinuation and switching. There are currently few large studies offering estimates of drug persistence with NOACs. Moreover, little is known about what drives patients’ choice and behavior regarding patterns of long-term medication use. Using a large heterogeneous cohort of patients, we aimed to investigate the patterns and predictors of switch and discontinuation amon...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: X Yao, ND Shah, LR Sangaralingham, BJ Gersh, PA Noseworthy Tags: CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient Preference Studies Source Type: research
The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research
